Illumina, Inc. (NASDAQ:ILMN) – Equities researchers at Leerink Swann cut their Q4 2017 earnings estimates for Illumina in a report released on Tuesday. Leerink Swann analyst P. Souda now expects that the life sciences company will earn $1.19 per share for the quarter, down from their previous forecast of $1.20. Leerink Swann has a “Outperform” rating and a $225.00 price objective on the stock. Leerink Swann also issued estimates for Illumina’s Q1 2018 earnings at $1.02 EPS, Q2 2018 earnings at $1.14 EPS, Q3 2018 earnings at $1.18 EPS and FY2018 earnings at $4.60 EPS.
ILMN has been the subject of a number of other research reports. Vetr upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $197.84 price target for the company in a research note on Tuesday, June 27th. BidaskClub downgraded shares of Illumina from a “hold” rating to a “sell” rating in a research note on Thursday, August 17th. Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. J P Morgan Chase & Co reiterated an “overweight” rating and issued a $250.00 price target on shares of Illumina in a research note on Wednesday, August 2nd. Finally, First Analysis upgraded shares of Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 price target for the company in a research note on Wednesday, August 2nd. Three analysts have rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $178.51.
ILLEGAL ACTIVITY WARNING: This story was posted by Stock Observer and is the sole property of of Stock Observer. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.thestockobserver.com/2017/09/13/leerink-swann-comments-on-illumina-inc-s-q4-2017-earnings-ilmn.html.
Illumina (NASDAQ ILMN) opened at 213.93 on Wednesday. The company’s 50 day moving average is $193.58 and its 200 day moving average is $179.25. The company has a market cap of $31.23 billion, a price-to-earnings ratio of 42.92 and a beta of 0.81. Illumina has a 1-year low of $119.37 and a 1-year high of $214.04.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.68 by $0.14. The firm had revenue of $662.00 million during the quarter, compared to analyst estimates of $642.38 million. Illumina had a net margin of 30.27% and a return on equity of 19.69%. Illumina’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.86 EPS.
Several institutional investors have recently made changes to their positions in ILMN. Advisory Services Network LLC increased its stake in Illumina by 13.0% in the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after buying an additional 89 shares during the period. Penserra Capital Management LLC increased its stake in Illumina by 13.0% in the 2nd quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock valued at $153,000 after buying an additional 102 shares during the period. Paradigm Asset Management Co. LLC increased its stake in Illumina by 5.6% in the 2nd quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after buying an additional 50 shares during the period. Patten Group Inc. increased its stake in Illumina by 2.7% in the 1st quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after buying an additional 25 shares during the period. Finally, NN Investment Partners Holdings N.V. increased its stake in Illumina by 11.3% in the 2nd quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock valued at $171,000 after buying an additional 100 shares during the period. 93.34% of the stock is currently owned by institutional investors and hedge funds.
In other news, Director Jay T. Flatley sold 15,000 shares of Illumina stock in a transaction on Tuesday, July 18th. The shares were sold at an average price of $170.77, for a total value of $2,561,550.00. Following the transaction, the director now directly owns 534,176 shares of the company’s stock, valued at approximately $91,221,235.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mostafa Ronaghi sold 20,000 shares of Illumina stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $210.00, for a total transaction of $4,200,000.00. Following the completion of the transaction, the senior vice president now directly owns 86,725 shares in the company, valued at $18,212,250. The disclosure for this sale can be found here. Insiders sold a total of 165,705 shares of company stock worth $31,202,418 over the last ninety days. Corporate insiders own 1.60% of the company’s stock.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.